If you look at the latest annual financial, total expenditure cost was $50M with a net loss of $24M ($12M directly from ADAPT segment), nearly half of the expenditure was due to employee salary of $23.5M, $3.5M are directors salaries with the other employee averaging $200K (this was $150K the previous year) and well over the Australia's average salary of $80K.
This is why their cash burn has been so high.......you wouldn't mind getting a job there and earning well over 2x the average salary.
Ann: CardioCel and VascuCel rights sold to LeMaitre Vascular, page-142
-
- There are more pages in this discussion • 148 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.35 |
Change
0.040(0.22%) |
Mkt cap ! $352.7M | |||
| Open | High | Low | Value | Volume |
| $19.00 | $19.00 | $18.13 | $69.15K | 3.766K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 383 | $18.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.50 | 1000 | 1 |
View Market Depth
| Last trade - 15.59pm 02/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |